Related Experiment Video

Updated: Jun 12, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Iodinated contrast media alter immune responses in pro-inflammatory states

David H O'Donnell1, Michael A Moloney, David J Bouchier-Hayes

  • 1Department of Radiology and Vascular Surgery, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland.

Acta Radiologica (Stockholm, Sweden : 1987)
|June 10, 2010
PubMed

Insights

Iodine contrast media, used in medical imaging, reduce the inflammatory response of white blood cells (leukocytes) to endotoxin. This effect was observed in vivo, demonstrating a protective role against endotoxin-induced inflammation.

Area of Science:

  • Biomedical Science
  • Pharmacology
  • Immunology

Background:

  • Hypertonic saline and iodine contrast media transiently increase blood osmolality.
  • Elevated blood osmolality can modulate cellular inflammatory responses.

Purpose of the Study:

  • To investigate the in vivo effect of iodine contrast media on leukocyte-endothelial interactions.
  • To assess how contrast media influence inflammatory responses mediated by leukocytes.

Main Methods:

  • Intravital microscopy was used in male Sprague-Dawley rats.
  • Rats were randomized into groups receiving saline, contrast media, or endotoxin (alone or with contrast media).
  • Leukocyte rolling velocity, adherence, and transmigration were quantified over 120 minutes.

Main Results:

  • Endotoxin induced a time-dependent increase in leukocyte adherence and transmigration, and decreased rolling velocity.
  • Both high and low osmolar iodine contrast media attenuated the endotoxin-induced pro-inflammatory leukocyte response.
  • The attenuating effect of contrast media became apparent between 60 and 70 minutes.

Conclusions:

  • Hyperosmolar and low osmolar iodine contrast media demonstrate an in vivo anti-inflammatory effect.
  • Contrast media attenuate the pro-inflammatory leukocyte-endothelial cell interactions triggered by endotoxin.
Abstract

More Related Videos

Induction of Ocular Surface Inflammation and Collection of Involved Tissues06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

Related Concept Videos

Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...